Clinical Trials
5 trialsNCT00324220 2015-07-01
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
Mirati Therapeutics Inc.
Phase 1/2 Completed
NCT00374296 2015-07-01
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT00666497 2015-05-08
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT00324129 2015-01-08
A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes
Mirati Therapeutics Inc.
Phase 1 Completed
NCT00324194 2015-01-08
A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes
Mirati Therapeutics Inc.
Phase 1 Completed